General Atomics Awarded U.S. Space Force Contract for Phase 2 of the Enterprise Space Terminal Program
"GA-EMS, under a Phase 1 contract award, leveraged its extensive Optical Communication Terminal (OCT) expertise to develop a design that can be efficiently scaled to deploy a mesh network enterprise of OCTs with capabilities to transfer large volumes of data between spacecraft and ground stations distributed across a wide spectrum of operational domains," said Scott Forney, president of GA-EMS. "We are excited to enter Phase 2 to advance our system design and begin the build and test of the OCT subsystems."
Phase 2 will include lab demonstrations of OCT subsystems within a government provided test bed. GA-EMS will continue design and analyses activities to optimize the system designs. Testing results and analyses will then be presented during a Critical Design Review (CDR) at the end of Phase 2 period of performance.
"The Phase 2 CDR will help inform the decision gate toward entering Phase 3 of the program, which will call for the assembly, test, and delivery of an integrated prototype OCT system for demonstration on a government provided test bed," said Gregg Burgess, vice president of GA-EMS Space Systems. "We look forward to delivering a robust, producible Optical Communication Terminal for the Space Force to ensure resilient space network connectivity for future National Security Space Architectures."
GA-EMS completed the preliminary design of the payload support system, electrical hardware, laser terminal design, optical design and subsystem, thermal control, and command and data handling under the EST Phase 1 contract awarded in 2024. As prime contractor, GA-EMS has teamed with L3Harris for the modem subsystem and Advanced Space to provide performance modelling.
SOURCE: General Atomics Electromagnetic Systems
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
3 hours ago
- Indianapolis Star
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
SHELTON, CT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union. NV-387 is possibly the only drug candidate that has been shown to be effective and safe in animal model studies of Measles virus in humanized h-CD150+ knock-in mice, as reported previously by NanoViricides. NV-387 has completed a Phase I clinical trial with no reported adverse events, indicating excellent safety and tolerability in humans. The development of NV-387 as a treatment for Measles can be accelerated under the US FDA programs. Measles is considered a rare orphan disease in the USA. As such, NV-387 for the treatment of Measles would qualify for an Orphan Drug Designation. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval [1]. The Company also plans to explore a 'Fast Track' designation for the NV-387 Measles indication. If granted, a drug approval can occur on the basis of a successful Phase II clinical trial without requiring a Phase III clinical trial, which significantly reduces the timeline to approval. Measles has become an important disease of concern globally in the recent years for several reasons. Most importantly, Measles disease can wipe out the previously learned immunity of the patient against many infections, including from prior infections, and non-live virus vaccines, making the population vulnerable to viruses that were encountered previously. This is because Measles virus attacks the CD150-bearing immune cells that are responsible for memorizing the prior infections and mounting defenses against them later. Measles is possibly the most communicable diseases, spreading through aerosol, that is known to humans. In patients, it produces severe morbidity with skin rash, pain, fatigue, and other syndromes. Rarely it can cause a brain disease. Measles mostly affects children. There were a total of 1,319 confirmed measles cases reported in the USA as of July 22, breaking the most recent record of 1,274 cases in 2019. Hospitalization rates for measles in the USA are about 13%, and fatalities are rare, although in 2025 there were three deaths to date. Canada is having a much worse Measles season than the USA, with more than 3,800 cases [2] to date in 2025. A Measles holiday warning has been issued in the UK this year [3]. England itself had more than 3,000 cases of Measles in 2024. In the European Region, 127,350 measles cases were reported for 2024, double the number of cases reported for 2023 and the highest number since 1997, according to an analysis by WHO and the United Nations Children's Fund (UNICEF) [4]. Worldwide, Measles cases continue to occur every year. Globally, there have been about 108,000 confirmed measles cases in 2025 to date, while in 2024 there were about 360,000 confirmed cases, according to the WHO [5]. A sustained measles vaccination rate of at least 95% is estimated to be required to maintain community immunity ('herd immunity'). Such a high rate is becoming increasingly difficult to achieve even in developed countries where access to vaccination is not an issue. While growing vaccine hesitancy is considered an important reason for the fall in Measles vaccination rates, two other factors are of importance as well: (i) The overall population in the industrialized world, as well as in developing world, has increased frequency of immune dysfunction, obesity, and diabetes. The people with immune dysfunction or immune compromise are less likely to benefit from almost any standard vaccination as compared to healthy people and are likely to result in breakthrough infections. (ii) Additionally, the current vaccine for Measles is a live attenuated vaccine of the 1968 era, and the virus has evolved well past that, although so far the Measles virus strains continue to be susceptible to antibodies produced from the standard vaccine; this can change with continuing circulation of the virus in vaccinated persons and can result in a virus that can substantially defeat the vaccine [6]. Further, vaccine hesitancy itself is not irrational because the standard Measles vaccine is a live attenuated vaccine to be given to infants at early age; it is a virus infection that continues to remain in the subject, which is why it provides lifelong immunity. Measles infection itself also provides lifelong immunity that includes the current strains of the virus. Thus, the Company projects continuing Measles cases worldwide, that require a drug to control the disease in the patient and its spread to others. We believe NV-387 fills this important medical need. There is no approved drug for treatment of Measles at present. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ View the original press release on ACCESS Newswire The post Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides appeared first on DA80 Hub.
Forbes
20 hours ago
- Forbes
ChatGPT 5: A New Model From OpenAI
It was a big day over at OpenAI. First, Sam Altman came onstage to kick off a livestream at 1:00 EST (10:00 PST) in which the company unveiled the new ChatGPT5 model that's going to boost the capability of the LLM. Calling the new model 'a significant step along our path to AGI,' Altman described GPT5 as like having a team of in any given subject to help you through a project or question. The model, he said, is also very versatile. 'It can do stuff for you,' he said. Next, a team of employees showed off how GPT5 scores on benchmarks including SWE, Aider Polyglot, MMMU and AIME 2025. In terms of reliability, presenters showed how transparency will help, and how more painstaking work can address any hallucinations that might occur. GPT5, they explain, will also be better at mitigating deception, which can happen, for example, when a model is under pressure and wants to hide something. Multimodal Design In addition, teams showed off the new model's voice capabilities, which are going to change how we interact with the technology. In going over some translation tasks, they showed how GPT5 can imitate various accents, speak at different speeds, and generally seem highly authentic in a range of languages. New Features and Engineering A tech also went over many of the new features in ChatGPT 5. There will be three different options in this model: a regular GPT5, a GPT5 mini, and a nano version able to run well on end devices, to help customers handle the 'cost-latency curve' of the tech. In addition, GPT5 will allow for a minimal reasoning effort, or allow users to trade off between time and power of response. A custom tools feature will help developers to go beyond the routine use of JSON as a standard. A verbosity parameter will help users to control how wordy the model's answers are, and tool call preambles build robustness into responses. Along the way, OpenAI people provided a range of demos including 'mini-games,' a mouse chasing cheese with French words as targets, a visual explanation of the Bernoulli effect, and what appeared to be a castle game with intrusive meteors. Notes on Development OpenAI president Greg Brockman took the stage later to show how power users are building creatively with GPT5. 'Software engineering is already fundamentally changing, and GPT5 will turbo-charge that revolution,' Brockman said. 'GPT5 sets a whole new standard. It is the best model at agentic coding tasks. You can ask it to go and accomplish something very complicated, and it'll go off and it'll work on it. It'll call many tools. It'll work for many minutes at a time, sometimes even longer, to accomplish your goal, your instruction, your tasks, whatever it is that you're trying to build. It's incredible at the front end. It makes very beautiful visualizations and interactive games.' One team member after the other unveiled relevant use cases: evaluating an API system, troubleshooting with an SDK, fixing a bug. 'Benchmarks, they're exciting numbers, but we're starting to saturate them,' Brockman said. 'Like when you're moving between 98% and 99% of a benchmark, it means you need something else to really capture how great the model is. One thing we've done very differently with this model is really focus on not just these numbers, but really on real-world applications, being really useful to you in your daily workflow. So that hearing about it is as exciting as seeing it.' Team members estimated that 5 million businesses worldwide are already dependent on GPT. The consensus seemed to be that this number is about to grow precipitously. That's big news for today, partly because this new model is rolling out to all OpenAI user tiers. Even free users will get some form of use of GPT5. So if you have any kind of task that prior versions tried to handle, the new one will do it faster, more thoroughly, and with more agentic capabilities. Stay tuned.
Miami Herald
20 hours ago
- Miami Herald
Unusual Machines to Announce Second Quarter 2025 Financial Results and Provide Corporate Update
ORLANDO, FLORIDA / ACCESS Newswire / August 7, 2025 / Unusual Machines (NYSE AMERICAN:UMAC), a leading provider of NDAA-compliant drone components, today announces that it will host a live webcast on Thursday, August 14th at 4:30 p.m. to discuss the Company's financial results and provide a corporate update for the second quarter ended June 30, 2025. A question-and-answer session will follow management's remarks. Event: Unusual Machines Second Quarter Ended June 30, 2025 Financial Results and Corporate Update Date: Thursday, August 14, 2025 Time: 4:30 p.m. Eastern Time Webcast: Registration Link A webcast replay will be available for three months on Unusual Machine's Investor Relations website for those who cannot join the live event. About Unusual Machines Unusual Machines manufactures and sells drone components and drones across a diversified brand portfolio, which includes Fat Shark, the leader in FPV (first-person view) ultra-low latency video goggles for drone pilots. The Company also retails small, acrobatic FPV drones and equipment directly to consumers through the curated Rotor Riot e-commerce store. With a changing regulatory environment, Unusual Machines seeks to be a dominant Tier-1 parts supplier to the fast-growing multi-billion-dollar U.S. drone industry. According to the global drone accessories market is currently valued at $17.5 billion and is set to top $115 billion by 2032. For more information, please visit Investor Contact CS Investor Relationsinvestors@ SOURCE: Unusual Machines, Inc.
